全文获取类型
收费全文 | 69757篇 |
免费 | 6492篇 |
国内免费 | 2219篇 |
专业分类
耳鼻咽喉 | 946篇 |
儿科学 | 767篇 |
妇产科学 | 713篇 |
基础医学 | 9353篇 |
口腔科学 | 2606篇 |
临床医学 | 6634篇 |
内科学 | 7850篇 |
皮肤病学 | 764篇 |
神经病学 | 4192篇 |
特种医学 | 1873篇 |
外国民族医学 | 4篇 |
外科学 | 4535篇 |
综合类 | 10684篇 |
现状与发展 | 7篇 |
一般理论 | 1篇 |
预防医学 | 6425篇 |
眼科学 | 1601篇 |
药学 | 9914篇 |
187篇 | |
中国医学 | 6178篇 |
肿瘤学 | 3234篇 |
出版年
2024年 | 112篇 |
2023年 | 1165篇 |
2022年 | 1869篇 |
2021年 | 3295篇 |
2020年 | 2966篇 |
2019年 | 2226篇 |
2018年 | 2181篇 |
2017年 | 2425篇 |
2016年 | 2577篇 |
2015年 | 2751篇 |
2014年 | 4678篇 |
2013年 | 5480篇 |
2012年 | 4293篇 |
2011年 | 4640篇 |
2010年 | 3565篇 |
2009年 | 3290篇 |
2008年 | 3251篇 |
2007年 | 3377篇 |
2006年 | 2829篇 |
2005年 | 2413篇 |
2004年 | 2097篇 |
2003年 | 1790篇 |
2002年 | 1507篇 |
2001年 | 1326篇 |
2000年 | 1111篇 |
1999年 | 997篇 |
1998年 | 830篇 |
1997年 | 737篇 |
1996年 | 671篇 |
1995年 | 699篇 |
1994年 | 681篇 |
1993年 | 618篇 |
1992年 | 572篇 |
1991年 | 537篇 |
1990年 | 456篇 |
1989年 | 426篇 |
1988年 | 401篇 |
1987年 | 380篇 |
1986年 | 393篇 |
1985年 | 509篇 |
1984年 | 414篇 |
1983年 | 264篇 |
1982年 | 376篇 |
1981年 | 235篇 |
1980年 | 208篇 |
1979年 | 192篇 |
1978年 | 128篇 |
1977年 | 113篇 |
1976年 | 104篇 |
1975年 | 61篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
目的 多样的环境因素使得不同产地栽培滇重楼的化学成分也丰富多样,不同居群栽培滇重楼的甾体皂苷类成分具有很大的差异,多源数据融合分析能更全面的表征药材化学信息,建立一个高效而准确的产地鉴别模型,为其资源合理开发利用提供依据。方法 以来自云南和四川的8个产地(保山、楚雄、大理、红河、丽江、成都、文山、玉溪)共366份栽培滇重楼根茎为实验材料,采集其傅里叶变换近红外光谱(FT-NIR)和衰减全反射-傅里叶变换中红外光谱(ATR-FTMIR)数据。采用Kennard-Stone算法将不同产地的样品分为2/3的训练集和1/3的预测集,基于4种特征变量提取方法(CARS、VIP、SPA、SO-Covsel)结合2种数据融合策略(低级数据融合和中级数据融合),建立偏最小二乘产地判别分析模型。根据模型参数交叉验证均方根误差(RMSECV)和预测均方根误差(RMSEP)评估模型的稳定性,模型训练集和预测集准确率(ACC)评估模型分类性能。结果 近红外光谱和中红外光谱均能反应不同产地栽培滇重楼的化学成分差异,在中级数据融合中,基于VIP和SPA提取的特征变量建立的模型正确率均大于94%。相较于中级数据融合,低级数据融合模型得到了最为满意的结果,其预测集分类正确率达到100%。结论 根据近红外和中红外数据建立的低级数据融合PLS-DA模型,能够用于栽培滇重楼的产地鉴别分析。 相似文献
2.
《Vaccine》2022,40(30):4038-4045
PurposeAs protection from COVID-19 following two doses of the BNT162b2 vaccine showed a time dependent waning, a third (booster) dose was administrated. This study aims to compare the antibody response following the third dose versus the second and to evaluate post-booster seroconversion.MethodsA prospective observational study conducted in Maccabi Healthcare Services. Serial SARS-CoV-2 Spike IgG tests, 1,2,3 and 6 months following the second vaccine dose and one month following the third were obtained. Neutralizing antibody levels were measured in a subset of participants. Per individual SARS-CoV-2 Spike IgG titer ratios were calculated one month after the booster administration compared to titers one month following the second dose and prior to booster.ResultsAmong 110 participants, 56 (51%) were women. Mean age was 61.7 ± 1.9 years and 66 (60%) were immunocompromised. One month after third dose, IgG titers were induced 7.83 (95 %CI 5.25–11.67) folds and 2.40 (95 %CI 1.90–3.03) folds compared to one month after the second, in the immunocompromised and immunocompetent groups, respectively. Of the 17 immunocompromised participants who were seronegative after the second dose, 4 (24%) became seropositive following the third. Comparing the titers prior to the third dose, an increase of 50.7 (95 %CI 32.5–79.1) fold in the immunocompromised group and 25.7 (95 %CI 19.1–34.7) fold in and immunocompetent group, was observed.ConclusionA third BNT162b2 vaccine elicited robust humoral response, superior to the response observed following the second, among immunocompetent and immunocompromised individuals. 相似文献
3.
4.
《Revista de gastroenterologia de Mexico》2022,87(1):52-58
IntroductionThe sofosbuvir-velpatasvir (SOF/VEL) combination is a direct-acting antiviral therapy that is authorized and available in Mexico, making the performance of a real-world multicenter study that evaluates the sustained virologic response at 12 weeks post-treatment a relevant undertaking.MethodsA retrospective review of the case records of 241 patients seen at 20 hospitals in Mexico was conducted to assess hepatitis C treatment with the SOF/VEL combination (n = 231) and the sofosbuvir/velpatasvir/ribavirin (SOF/VEL/RBV) combination (n = 10). The primary efficacy endpoint was the percentage of patients that achieved SVR at 12 weeks after the end of treatment.ResultsOverall SVR was 98.8% (95% CI 97.35-100%). Only three patients did not achieve SVR, two of whom had cirrhosis and a history of previous treatment with peg-IFN. Of the subgroups analyzed, all the patients with HIV coinfection, three patients with genotype 3, and the patients treated with the SOF/VEL/RBV combination achieved SVR. The subgroups with the lower success rates were patients that were treatment-experienced (96.8%) and patients with F1 fibrosis (95.5%). The most frequent adverse events were fatigue, headache, and insomnia. No serious adverse events were reported.ConclusionTreatments with SOF/VEL and SOF/VEL/RBV were highly safe and effective, results coinciding with those of other international real-world studies. 相似文献
5.
6.
《Vaccine》2022,40(31):4105-4115
The etiologic agents of visceral leishmaniasis are Leishmania infantum and Leishmania donovani. Despite the variety of drugs available to treat leishmaniasis, most lead to serious adverse effects, and resistance to these drugs has been reported. Currently, no leishmaniasis vaccine is available for humans. That is why the group developed transgenic L. infantum promastigote lines, which express toxic proteins after differentiation into amastigotes. That is why group developed the pFL-AMA plasmid and transfected it into L. Infantum promastigotes. This plasmid was expressed only in the amastigote form of the parasite. Sequences encoding toxic proteins (active bovine trypsin and egg avidin) were inserted in this plasmid, and the transfected parasites died after the differentiation process. In this study, two immunization protocols were performed in BALB/c mice: prime and prime-boost immunization prior to challenge with the wild-type L. infantum (WT). The parasite burdens in the spleen, liver, and bone marrow were evaluated to verify immunological protection. Histopathological analysis of the spleen and liver and the humoral immune response were also performed. The data showed that the parasite burden was reduced in prime-boosted mice in the spleen, liver, and bone marrow, indicating that mice immunized with two doses of the transfected parasites were satisfactorily protected. High levels of IgG, IgG1, and IgG2a antibodies were observed, as well as the presence of anti-inflammatory cytokine Interleukine-10 and pro-inflammatory cytokine Tumor Necrosis Factor-α (TNF-α) and Interferon-γ (IFN – γ) suggesting a Th1/Th2 mix response, in addition to the presence of multinucleated giant cells in the spleen and lymphocyte infiltration in the liver. Therefore, L. infantum transfected with a toxic plasmid is an excellent vaccine candidate against visceral leishmaniasis and the application of a boost before the challenge promotes greater protection against WT L. infantum infection. 相似文献
7.
《Orthopaedics and Trauma》2022,36(6):304-310
Congenital vertical talus (CVT) is a rare foot deformity that presents with a rigid flat foot at birth. CVT can present as an isolated abnormality in the newborn, however in at least 50% of cases in association with other conditions. Full neuro-axial imaging is essential to detect any associated neurologic problems. Radiographs of the foot, including forced plantar and dorsiflexion laterals, are diagnostic. Gold standard modern treatment uses the Dobbs method of serial manipulation and casting with minimally-invasive stabilization of the talonavicular joint and Achilles tendon tenotomy. 相似文献
8.
9.
Robert J. Motzer MD David F. McDermott MD Bernard Escudier MD Mauricio Burotto MD Toni K. Choueiri MD Hans J. Hammers MD PhD Philippe Barthélémy MD PhD Elizabeth R. Plimack MD Camillo Porta MD Saby George MD Thomas Powles MD Frede Donskov MD PhD Howard Gurney MD Christian K. Kollmannsberger MD Marc-Oliver Grimm MD Carlos Barrios MD Yoshihiko Tomita MD PhD Daniel Castellano MD Viktor Grünwald MD PhD Brian I. Rini MD M. Brent McHenry PhD Chung-Wei Lee MD PhD Jennifer McCarthy MA Flavia Ejzykowicz PhD Nizar M. Tannir MD 《Cancer》2022,128(11):2085-2097
10.